179 related articles for article (PubMed ID: 24825858)
1. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.
Parameswaran R; Lim M; Fei F; Abdel-Azim H; Arutyunyan A; Schiffer I; McLaughlin ME; Gram H; Huet H; Groffen J; Heisterkamp N
Mol Cancer Ther; 2014 Jun; 13(6):1567-77. PubMed ID: 24825858
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma.
Onda K; Iijima K; Katagiri YU; Okita H; Saito M; Shimizu T; Kiyokawa N
Int J Hematol; 2010 Jun; 91(5):808-19. PubMed ID: 20428981
[TBL] [Abstract][Full Text] [Related]
3. Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies
Qin H; Wei G; Sakamaki I; Dong Z; Cheng WA; Smith DL; Wen F; Sun H; Kim K; Cha S; Bover L; Neelapu SS; Kwak LW
Clin Cancer Res; 2018 Mar; 24(5):1114-1123. PubMed ID: 29180606
[No Abstract] [Full Text] [Related]
4. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.
Parameswaran R; Müschen M; Kim YM; Groffen J; Heisterkamp N
Cancer Res; 2010 Jun; 70(11):4346-56. PubMed ID: 20460528
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions.
Dong Z; Cheng WA; Smith DL; Huang B; Zhang T; Chang WC; Wang X; Forman SJ; Kwak LW; Qin H
Cancer Immunol Immunother; 2020 Oct; 69(10):2139-2145. PubMed ID: 32451682
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies.
Mihalcik SA; Tschumper RC; Jelinek DF
Cell Cycle; 2010 Dec; 9(24):4884-92. PubMed ID: 21099364
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.
Vicioso Y; Gram H; Beck R; Asthana A; Zhang K; Wong DP; Letterio J; Parameswaran R
Cancer Immunol Res; 2019 Jul; 7(7):1106-1119. PubMed ID: 31138521
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
[TBL] [Abstract][Full Text] [Related]
9. BAFF receptor antibody for mantle cell lymphoma therapy.
Zhang K; Roy NK; Vicioso Y; Woo J; Beck R; de Lima M; Caimi P; Feinberg D; Parameswaran R
Oncoimmunology; 2021 Mar; 10(1):1893501. PubMed ID: 33747637
[TBL] [Abstract][Full Text] [Related]
10. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies.
Matlawska-Wasowska K; Ward E; Stevens S; Wang Y; Herbst R; Winter SS; Wilson BS
Leukemia; 2013 Jun; 27(6):1263-74. PubMed ID: 23307031
[TBL] [Abstract][Full Text] [Related]
11. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
Rafiq S; Siadak A; Butchar JP; Cheney C; Lozanski G; Jacob NK; Lapalombella R; McGourty J; Moledor M; Lowe R; Setter B; Jones J; Flynn JM; Andritsos L; Devine S; Mo X; Jarjoura D; Tridandapani S; Algate P; Byrd JC; Muthusamy N
MAbs; 2013; 5(5):723-35. PubMed ID: 23883821
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
13. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
[TBL] [Abstract][Full Text] [Related]
14. Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies.
Dong Z; Song JY; Thieme E; Anderson A; Oh E; Cheng WA; Kuang BZ; Lee V; Zhang T; Wang Z; Szymura S; Smith DL; Zhang J; Nian W; Zheng X; He F; Zhou Q; Cha SC; Danilov AV; Qin H; Kwak LW
Blood Adv; 2023 Mar; 7(6):918-932. PubMed ID: 36469551
[TBL] [Abstract][Full Text] [Related]
15. Rescue of the mature B cell compartment in BAFF-deficient mice by treatment with recombinant Fc-BAFF.
Swee LK; Tardivel A; Schneider P; Rolink A
Immunol Lett; 2010 Jun; 131(1):40-8. PubMed ID: 20350570
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.
Tsai LK; Pop LM; Liu X; Vitetta ES
Toxins (Basel); 2011 Apr; 3(4):409-19. PubMed ID: 22069716
[TBL] [Abstract][Full Text] [Related]
17. A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells.
McClements M; Williams S; Ball C; Bristow A; Wadhwa M; Meager A
J Immunol Methods; 2008 Aug; 337(1):63-70. PubMed ID: 18625509
[TBL] [Abstract][Full Text] [Related]
18. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
19. Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.
Seidel UJ; Schlegel P; Grosse-Hovest L; Hofmann M; Aulwurm S; Pyz E; Schuster FR; Meisel R; Ebinger M; Feuchtinger T; Teltschik HM; Witte KE; Schwarze CP; Rammensee HG; Handgretinger R; Jung G; Lang P
Mol Ther; 2016 Sep; 24(9):1634-43. PubMed ID: 27380762
[TBL] [Abstract][Full Text] [Related]
20. Impact of BAFF Blockade on Inflammation, Germinal Center Reaction and Effector B-Cells During Acute SIV Infection.
Borhis G; Trovato M; Ibrahim HM; Isnard S; Le Grand R; Bosquet N; Richard Y
Front Immunol; 2020; 11():252. PubMed ID: 32194549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
